ClinicalTrials.gg
RecruitingNCT07052084SAVSepticShockUpdated Oct 26, 2026

Systematic Adjunction of Vasopressine in Septic Shock

A Phase 3 interventional study of Vasopressin administration and Sodium chloride administration in Septic Shock, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Assistance Publique Hopitaux De Marseille · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 184 studies in Shock, Septic with a site in France — 45 open to participants now, 50 under way, 7 of them phase 3. Shock, Septic · France.

Planned enrollment
52nd of 105
120 · median 120
Started
2026
with 16 others
Phase 3
25 of 184
6 open now
Primary completion
2028-02
later than 36 of 49 live
Registered
166th of 184
by date
Lead sponsor
6 of 184
Assistance Publique Hopitaux De Marseille

Among the 184 studies in Shock, Septic with a site in France, this one is the 52nd largest by planned enrollment of the 105 interventional ones that give a count, is one of 17 that started in 2026, is one of 25 in phase 3, reaches primary completion later than 36 of the 49 other live ones, and was the 166th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

45 of the 184 studies in Shock, Septic with a site in France are open now. Recruiting first, the newest first:

39 more — sign in →

All 45 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Shock, Septic with a site in France, or all of them as a file.
02

Study summary

Septic shock is a syndrome associated with severe infection and a mortality rate of approximately 45%. In line with current recommendations, norepinephrine is the first-line vasopressor used in patients with septic shock. In a previous study, norepinephrine doses above 1 µg/kg/min were associated with mortality rates over 90%. In the same study, doses above 0.3 µg/kg/min were associated with a mortality rate of 40%. An increased mortality compared to the general 40% mortality of septic shock appears to be associated with norepinephrine doses as low as 0.3 µg/kg/min.

Vasopressin stimulates V1 receptors, primarily located on vascular smooth muscle cells. When V1a receptors are stimulated, they induce vasoconstriction by activating protein kinase C via a Gq protein and various second messengers.

Its use is validated in refractory shock states by international guidelines as a second-line vasopressor. This indication was further reinforced in the 2021 update of the septic shock management recommendations.

The VASST study, a randomized controlled trial, assessed the effects of vasopressin versus norepinephrine in septic shock. It found no overall difference in mortality between the two groups. However, in less severe cases where norepinephrine doses were below 14 µg/min before randomization, vasopressin was associated with significantly lower mortality, suggesting potential benefits from early introduction of a second vasopressor.

The VANISH trial failed to confirm this hypothesis, possibly due to broad inclusion criteria and unclear protocol regarding the combined use of both agents. Our hypothesis is that (1) vasopressin is beneficial when used synergistically with norepinephrine; (2) due to its negative effect on cardiac output (as shown in previous studies), vasopressin should only be administered to patients in the hyperdynamic phase of septic shock.

The hypothesis is that the systematic addition of vasopressin to norepinephrine therapy in a hyperdynamic septic shock subpopulation would improve patient outcomes.

03

Conditions studied

  • Septic Shock

Browse trials for

Keywords

  • Vasopressine
  • Systematic adjunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 18 or over
  • Patient who has consented to take part in the research or patient whose close relative has consented to take part in the research or, failing that, patient being included in an emergency situation
  • Patient in septic shock with adapted cardiac output
  • Patient in whom noradrenaline dosage has been greater than 0.3μg/kg/min for less than 12 hours
  • Patients benefiting from or affiliated to social security

Exclusion criteria

Exclusion Criteria:

  • Patient with acute coronary syndrome
  • Patient with known history of acute coronary syndrome
  • Patient with suspected mesenteric ischemia
  • Patient with hyponatremia \< 130mmol/L,
  • Known allergy to vasopressin or its
  • Minors
  • Pregnant women
  • Patients under legal guardianship or curatorship
  • Patients under judicial protection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Vassopressine

    Drug: Vasopressin administration

  • Placebo comparator
    Placebo

    Drug: Sodium chloride administration

Interventions

  • DrugVasopressin administration

    Low dose of vasopressin (0.02ui /min), maximum 5 days

  • DrugSodium chloride administration

    NaCl 0.9 %, maximum 5 days

06

What researchers measure

Primary outcomes

  1. SOFA score comparison between the two groups

    Sepsis-related Organ Failure Assessment, 0 to 24 points (higher scores indicate more severe organ dysfunction)

    Time frame: 48 hours after administration of experimental drug (H48)

Secondary outcomes

  1. SOFA score comparison between the two groups

    Sepsis-related Organ Failure Assessment, 0 to 24 points (higher scores indicate more severe organ dysfunction)

    Time frame: 120 hours after administration of experimental drug (H120)

  2. Mortality comparison between the two groups

    Time frame: 28 days after administration of experimental drug (D28)

  3. Lactatemia decrease comparison between the two groups

    Time frame: Between administration of experimental drug (H0), 24 hours after (H24), and 48 hours after (H48)

  4. Noradrenaline use comparison between the two groups

    Maximum dose

    Time frame: 5 days after administration of experimental drug (D5)

  5. Renal function comparison between the two groups

    Number of days alive without renal replacement therapy

    Time frame: 28 days after administration of experimental drug (D28)

  6. Respiratory function comparison between the two groups

    Number of days alive without mechanical ventilation

    Time frame: 28 days after administration of experimental drug (D28)

  7. Occurrence of myocardial ischemia comparison between the two groups

    Time frame: 28 days after administration of experimental drug (D28)

  8. Occurrence of cardiogenic shock comparison between the two groups

    Time frame: 28 days after administration of experimental drug (D28)

  9. Occurrence of mesenteric ischemia comparison between the two groups

    Time frame: 28 days after administration of experimental drug (D28)

  10. Occurrence of digital ischemia comparison between the two groups

    Time frame: 28 days after administration of experimental drug (D28)

  11. Occurrence of atrial fibrillation comparison between the two groups

    Time frame: 28 days after administration of experimental drug (D28)

  12. Occurrence of a thromboembolic event comparison between the two groups

    Time frame: 28 days after administration of experimental drug (D28)

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2028, 23 months after the start.

Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's planned 23 months is below that.

Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Mar 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 4, 2025
StartActual
Mar 24, 2026was Jan 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
2 sites added. Assistance Publique - Hôpitaux de Marseille is now Recruiting
Show 2 added (2 France)
  • Centre Hospitalier du Pays d'Aix · Aix-en-Provence, France
  • CHU de Nîmes - Carémeau · Nîmes, France
Oct 26, 2026
Start date
Jan 2026→Mar 24, 2026 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    2 sites added. Assistance Publique - Hôpitaux de Marseille is now Recruiting
    Show 2 added (2 France)
    • Centre Hospitalier du Pays d'Aix · Aix-en-Provence, France
    • CHU de Nîmes - Carémeau · Nîmes, France
    Start date Jan 2026→Mar 24, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07052084
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Mar 24, 2026
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Gary Duclos, MD
Contact
gary.duclos@ap-hm.fr
04 91 96 55 31 ext. +33
François Crémieux
study director · Assistance Publique - Hôpitaux de Marseille

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion